

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
'United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO. FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/475,365 06/04/2001	DR. PORUNELLOR A. MATHEW	91561/74891 6249	
23552 7590 02/04/200	2		
MERCHANT & GOULD PC		EXAMINER	
P.O. BOX 2903 MINNEAPOLIS, MN 55402-090		LI, RUIXIANG	
MINNEM CEIS, MIN 33402-050	,		
		ART UNIT	PAPER NUMBER
		1646	
		DATE MAILED: 02/04/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application N	0.	Applicant(s)			
Office Action Summary		09/475,365		MATHEW ET AL.			
		Examiner		Art Unit			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period for Reply							
THE ! - Exter after - If the - If NO - Failui - Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a reply a period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, he within the statutory will apply and will expire, cause the application	owever, may a reply be tim ninimum of thirty (30) days re SIX (6) MONTHS from n to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
1) 🖂							
2a)□	· · · · <u> </u>	his action is non-final.					
3)	, 	vance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) Claim(s) 1-21 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
	Claim(s) is/are rejected.						
•—	7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-21</u> are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abovenes. See 37 CER 1.85(s)							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No						
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment	-	- priority diluoi	23 0.0.0. 33 120				
2) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	4) [5) [6) [Notice of Informal P	(PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/475,365

Art Unit: 1646

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-12, drawn to polypeptides, classified in class 530, subclass 350.
 - II. Claims 13, 14, and 21, drawn to a nucleic acid and a host cell, classified in class 536, subclass 23.5 and class 435, subclass 325.
 - III. Claims 15 and 16, drawn to a method for inhibiting tumor cell growth, classified in class 514, subclass 2.
 - IV. Claims 17-19, drawn to an antibody, classified in class 530, subclass 387.9.
 - V. Claim 20, drawn to a method for reducing natural killer cell mediated rejection of a bone marrow graft, classified in class 514, subclass 2.
- 2. The inventions are distinct, each from the other for the following reasons. Inventions I, II, and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP §806.04, MPEP §808.01). In the instance case, the different inventions are drawn to completely different products having completely different structures and biological functions which are not interchangeable and which require non-cohesive searches and considerations.
- 3. Inventions III and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP §806.04, MPEP §808.01).
 In the instance case the different inventions are drawn to completely different

Application/Control Number: 09/475,365

Art Unit: 1646

methods each having completely different method steps and outcomes. Thus, the two methods are exclusive and require non-cohesive searches and considerations.

- 4. Invention I is related to Inventions III and V as product and process of use. The invention can be shown to be distinct if either or both of the following can be shown:
 (1) the process for using the product as can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP §806.05 (h)). In the instance case the peptide may be used in a materially different process such as to immunize with.
- 5. Invention II is unrelated to Inventions III and V; Invention IV is unrelated to Inventions III and V. The different inventions are drawn to distinct product and method inventions.
- 6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 7. Because these inventions are distinct for the reasons given above and the search required for a single group is not required for any other group, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48 (b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48 (b) and by the fee required under 37 CFR 1.17 (I).

Application/Control Number: 09/475,365

Art Unit: 1646

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (703) 306-0282. The examiner can normally be reached on Monday-Friday, 8:30 am-5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564. The fax phone number for this Group is (703) 305-3014 or (703) 308-4242.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

(Yeshand C. Kemmen

Ruixiang Li Examiner January 25, 2002 ELIZABETH KEMMERER
PRIMARY EXAMINER